Navigation Links
Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
Date:6/24/2008

xecutive officer. "Our partners at Astellas are the market leaders in the MPI market and are very well positioned for commercial success."

CV Therapeutics owns the rights for regadenoson outside of North America and currently expects to submit a marketing authorization application for the product to the European Medicines Agency by the end of 2008.

Astellas Pharma US, Inc. / CV Therapeutics Inc. Collaboration

Under a license and collaboration agreement providing Astellas with exclusive North American rights to Lexiscan(TM) (regadenoson) injection, CV Therapeutics completed the development program and Astellas is responsible for all commercial activities for the product in North America. Under the arrangement, Astellas paid CV Therapeutics a $7 million milestone upon submission of the new drug application to the FDA, and a $12 million milestone in April 2008. Astellas also reimburses CV Therapeutics for 75 percent of development costs. CV Therapeutics will receive a royalty on product sales of Lexiscan(TM) (regadenoson) injection, and may receive a royalty on another Astellas product.

About Lexiscan(TM) (regadenoson) injection

Lexiscan(TM) is an A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide MPI studies in patients unable to undergo adequate exercise stress. Lexiscan(TM) was designed to produce coronary vasodilation and increase coronary blood flow by activation of the A2A adenosine receptor. Lexiscan(TM) is administered as a rapid bolus (approximately 10 seconds) with no dose adjustment required for body weight. Lexiscan(TM) should not be administered to patients with second- or third-degree AV block or sinus node dysfunction who do not have a functioning artificial pacemaker. Adenosine receptor agonists, including Lexiscan(TM), induce arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with cardiac or cerebrovascular insufficiency. Comple
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. ADVENTRX Appoints Vice President of Commercialization
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
9. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - Portage Biotech ... Exchange: PBT.U), is pleased to announce that its three ... of Portage, who advanced $ 100,000 each in July ... have their Notes and related Coupons converted into 3,500,001 ... and carried 5% coupon. Both the Note and the ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ‘Peptide ... Application - Cancer, Metabolic, CVS, CNS & others, by ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... market was worth US$14.1 billion in 2011 and is ... 8.7% CAGR. , The two main types of peptide ...
(Date:9/29/2014)... METTLER TOLEDO’s new line of XPE balances includes ... balances as well as automated dosing with the ... out their daily weighing tasks worry free, safe in ... reliable and compliant results, thanks to new technologies such ... biggest challenges in analytical and micro-analytical weighing – electrostatic ...
(Date:9/29/2014)... Sept. 29, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced that ... granted multiple Orphan Drug Designations for the Company,s ... multiforme (GBM), small cell lung cancer and ovarian ... widely-used chemotherapeutic agent, doxorubicin. "The FDA,s ...
Breaking Biology Technology:Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3New Line of XPE Balances from METLER TOLEDO is Designed for High Performance and Ease of Compliance 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5
... California, San Diego electrical engineers have created experimental ... to highly efficient thin-film solar cells of the ... as electron superhighways that carry electrons kicked loose ... electron-attracting electrode and this scenario could boost ...
... Morrow, who will graduate from Rensselaer Polytechnic Institute on ... his days as an elementary school student, pulling apart ... developed two innovations that could vastly improve magnetic data ... everything from ink on counterfeit currency to tissue in ...
... improvement is achieved by the use of an ultra-thin aluminum ... brings a breakthrough in the use of solar energy a ... cent (in absolute terms) may at first glance appear modest, ... the performance of their products. This is because higher efficiency ...
Cached Biology Technology:Nanowires may boost solar cell efficiency, UC San Diego engineers say 2Nanowires may boost solar cell efficiency, UC San Diego engineers say 3Nanowires may boost solar cell efficiency, UC San Diego engineers say 4Commencement 2008: Student innovation could improve data storage, magnetic sensors 2New efficiency record for solar cells 2
(Date:9/29/2014)... received a five-year, $6 million grant for clinical ... and development of safe and effective treatments for ... the National Institutes of Health, National Institute on ... Medication Development for Cocaine Use Disorder to oversee ... decisions on moving forward with more expensive large-scale ...
(Date:9/29/2014)... culture, mathematics is often deemed inaccessible or esoteric. Yet ... important role in our daily lives and a decisive ... often behind the scenes. , UC Santa Barbara,s ... and an assistant professor of mechanical engineering, often works ... his recent research published in the Proceedings of ...
(Date:9/29/2014)... The U.S. Department of Energy Joint Genome Institute ... facility, has announced that 32 new projects have ... (CSP). From sampling Antarctic lakes to Caribbean waters, ... underneath the water table in forested watersheds, the ... DOE mission-relevant science can be extracted. , ...
Breaking Biology News(10 mins):New VCU center to target cocaine addiction 2At the interface of math and science 2At the interface of math and science 3At the interface of math and science 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9
... release is available in Spanish . , ... viable alternative to petroleum-based packaging products, according to a ... Tomasula for a new book, "Dairy-Derived Ingredients: Food ... by an international team of contributors and published by ...
... "original insect wrangler" who tamed 25,000 roaches, and trained ... of the Lambs," headlines the Southwest,s first Social Insect ... Garden. Designed for inquiring minds and families, the ... Arizona State University, their favorite critters and the public. ...
... breeding and high-intensity x-rays is being used by ... Research Council (BBSRC) to explore the possibility of ... potentially life-saving mineral enriched flour. The research is ... quarterly highlights magazine of BBSRC. Scientists from ...
Cached Biology News:Potential of dairy-based package wraps outlined 2Insect wranglers invade the garden at Southwestern science EXPO 2Scientists using X-ray vision to produce more nutritious flour 2
... The Rapid DNA Ligation ... or blunt-end DNA fragments in ... C. Depending on the ... DNA concentration) or concatemeric (high ...
... Polynucleotide Kinase catalyzes the transfer ... to the 5-terminus of polynucleotides ... 5-hydroxyl group. The enzyme, purified ... be used to phosphorylate RNA, ...
...
... CryoMed Freezers for IVF are designed for ... control, ease of setup and operation, and ... status are continuously displayed on the control ... data are printed by way of the ...
Biology Products: